Advances in the Understanding of Drug Hypersensitivity: 2012 Through 2022 - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Allergy and Clinical Immunology: In Practice Année : 2023

Advances in the Understanding of Drug Hypersensitivity: 2012 Through 2022

Résumé

Over the last decade there have been key advances in understanding mechanisms, risk, and consequences of both true immunological drug hypersensitivity and unverified drug allergy labels that have changed clinical practice. This has been facilitated by the widespread adoption of electronic health records (EHRs). The vast majority of EHR drug allergy labels are unverified and cause significant morbidity from unnecessary avoidance of optimal drug therapy. There has also been significant movement in our understanding of mechanisms of drug hypersensitivity that, in addition to advancing our understanding of the pathogenesis of immediate and delayed reactions, have guided preventive efforts, diagnostic procedures, and clinical management. More widespread adoption, including scale-up of "allergy" delabeling and appropriate management, specifically for antibiotics, opiates, radiocontrast, chemotherapeutics, biologics, and nonsteroidal anti-inflammatory medications, will be necessary to improve patient outcomes over the next decade. This will require further engagement and collaboration between primary care health care providers, allergists, and other specialists.

Domaines

Allergologie
Fichier non déposé

Dates et versions

hal-03930648 , version 1 (09-01-2023)

Identifiants

Citer

Eric Macy, Axel Trautmann, Anca Mirela Chiriac, Pascal Demoly, Elizabeth Phillips. Advances in the Understanding of Drug Hypersensitivity: 2012 Through 2022. Journal of Allergy and Clinical Immunology: In Practice, 2023, 11 (1), pp.80-91. ⟨10.1016/j.jaip.2022.10.025⟩. ⟨hal-03930648⟩
27 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More